Press Release | NeoGenomics Laboratories

May 5, 2022

NeoGenomics To Participate in the BofA Securities 2022 Healthcare Conference

April 27, 2022

NeoGenomics Reports Revenue of $117 Million in the First Quarter

April 25, 2022

NeoGenomics Inc. Announces Partnership with Lilly for Lung Cancer Sponsored Testing Program Utilizing the NeoTYPE(R) DNA and RNA Assay

April 11, 2022

NeoGenomics Announces That Inivata Liquid Biopsy Subsidiary and Collaborators Have Published Clinical Validation Data for RaDaR™ Assay MRD Assay at AACR 2022

April 11, 2022

NeoGenomics, Inc. Expands Its Global Strategic Partnership Initiatives with Biognosys AG on Multiple Next Generation Proteomics Solutions Supporting Biopharma R&D

April 8, 2022

NeoGenomics Schedules its First Quarter 2022 Earnings Release for April 27, 2022

March 17, 2022

NeoGenomics Announces That Inivata Liquid Biopsy Subsidiary and Collaborators Have Published Clinical Validation Data for RaDaR™ Assay in Non-Small Cell Lung Cancer

March 2, 2022

NeoGenomics To Participate In Multiple Upcoming Institutional Investor Conferences

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients